Rapid Weight Loss With Gallbladder Symptoms on a GLP-1 Agonist
A 39-year-old woman with BMI 34.2 kg/m² started tirzepatide 8 weeks ago and has lost 9 kg (9% of body weight). She now reports 6 hours of right upper quadrant pain radiating to the right scapula, worse after a fatty meal, with nausea but no fever or jaundice. Temperature 37.4°C, heart rate 96, blood pressure 124/78. She has no prior history of gallstones. She is anxious about stopping the medication and asks whether the drug caused this and whether she can continue it.
1. What is the differential diagnosis, what immediate evaluation is indicated, and how does the medication relate to the presentation?
Read the worked answer
Differential. Biliary colic or acute cholecystitis (most likely given the classic postprandial RUQ pain radiating to the scapula), choledocholithiasis, pancreatitis, hepatitis, peptic ulcer disease, and less likely right-sided renal or pulmonary causes.
Immediate evaluation. RUQ ultrasound, CBC, comprehensive metabolic panel including liver enzymes, lipase if pain is epigastric or persistent, and urinalysis. If fever, jaundice, or hemodynamic instability develop, escalate urgently (surgical consultation, consider MRCP if choledocholithiasis suspected).
Relationship to the drug. Rapid weight loss is an established risk factor for gallstone formation and biliary complications; GLP-1 receptor agonist and dual agonist labels note increased cholecystitis events, largely mediated by rapid weight loss and gallbladder stasis. The temporal pattern (9% loss in 8 weeks) is consistent with this mechanism, though causation cannot be assigned in an individual patient.
Judgment. This is not a reason to reflexively discontinue the drug, but acute cholecystitis or choledocholithiasis would require acute management and a reassessment of the treatment plan.
2. Assuming ultrasound shows gallstones without cholecystitis, how do you counsel her about continuing tirzepatide and about the pace of weight loss?
Read the worked answer
Counseling.
- Uncomplicated cholelithiasis is not an absolute contraindication to continuing the medication, but recurrent biliary colic is a reason to involve surgery and consider cholecystectomy.
- Counsel on a low-fat diet and adequate hydration to reduce biliary colic triggers.
- Warn her to seek urgent care for fever, jaundice, persistent vomiting, or severe unrelenting pain.
Pace of loss. A 9% loss in 8 weeks is faster than typical and may increase gallstone risk. Consider whether the titration schedule was too rapid and whether dose escalation should be paused; slower loss reduces biliary risk without abandoning efficacy.
Shared decision. Document the discussion, the ultrasound findings, and the agreed plan. If she develops recurrent colic or cholecystitis, address the gallbladder first and then resume therapy with surgical input.
Key judgment. Avoid both extremes - neither ignoring the biliary risk nor permanently abandoning an effective therapy without a plan.